Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04987879 · ClinicalTrials.gov registry record · NA
NASH AMPK Exercise Dosing (AMPED) Trial
A NA study of NAFLD, sponsored by Milton S. Hershey Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT04987879 is a NA study of NAFLD that is actively recruiting participants, run by Milton S. Hershey Medical Center. The registered enrollment target is 45 participants, below the 163-participant average among 26 other NAFLD trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04987879, a NA study of NAFLD, is actively recruiting participants, sponsored by Milton S. Hershey Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD. While physical activity is recommended for all with NAFLD, how to best prescribe exercise as a specific treatment remains unknown, including what dose of exercise is most effective.
Conditions Studied
Interventions
- BEHAVIORAL Exercise
Study Locations (1)
Pennsylvania
- Penn State Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2026-07-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04987879
The ClinicalTrials.gov registry entry for NCT04987879 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 163-participant average among 26 other NAFLD trials with a reported enrollment target (72% lower). The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NAFLD appearing as the primary indexed condition, and to 1 intervention - of which Exercise is the first listed.
NCT04987879 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04987879 about?
NCT04987879 is a clinical study titled "NASH AMPK Exercise Dosing (AMPED) Trial". There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD. While physical activity is recommended for...
What is the current status of trial NCT04987879?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2022-08-30. Estimated completion is 2026-07-15.
What conditions does trial NCT04987879 study?
This clinical trial studies the following conditions: NAFLD.
What interventions are being tested in trial NCT04987879?
The interventions under investigation include: Exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT04987879?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04987879 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NAFLD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reversal of Lipid-Induced Insulin Resistance
RECRUITING · NA
-
NAFLD Clinical Care Pathway
RECRUITING · NA
-
Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD
ACTIVE NOT RECRUITING · NA
-
An Imaging-based Quantitative Biomarker Assay for NAFLD in Children
ACTIVE NOT RECRUITING · NA
-
The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)
COMPLETED · NA
-
Healthy Liver - Healthy Brain
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.